<DOC>
	<DOCNO>NCT01896557</DOCNO>
	<brief_summary>Previous report show possible drug interaction clopidogrel proton pump inhibitor ( PPI´s ) , could result increased number adverse cardiovascular event among patient dual antiplatelet therapy ( DAPT ) . Because , ranitidin propose alternative drug PPI´s prophylaxis gastrointestinal bleeding patient need DAPT . The study´s aim test hypothesis ranitidin doesn´t influence clopidogrel pharmacodynamic .</brief_summary>
	<brief_title>Ranitidin Versus Omeprazole Patients Taking Clopidogrel</brief_title>
	<detailed_description>Study population : 100 patient Stable Coronary Artery Disease Heart Institute Inclusion Criteria : - Age &gt; 18 year old - Coronary artery disease , define previous myocardial infarction and/or coronary angioplasty and/or Coronary Artery Bypass Graft ( CABG ) surgery and/or coronariography show obstruction least 50 % one major epicardial vessel - Treatment Acetylsalicylic Acid ( ASA ) 100 mg/day Exclusion Criteria : - Use last 7 day oral anticoagulant antiplatelet drug beside ASA - Previous utilization PPI ranitidine last 7 day randomization - Active bleeding - Pregnancy woman childbearing age without contraceptive method - Hemoglobin &lt; 10 g/dL hematocrit &lt; 30 % , hematocrit &gt; 50 % , platelet &lt; 100.000/mm3 &gt; 500.000/mm3 ; creatinin clearance &lt; 50 ml/minute - Percutaneous coronary intervention ( PCI ) last 30 day randomization ( PCI last year drug-eluted stent use ) ; CABG surgery last 90 day ; acute coronary syndrome last 60 day - Active malignant neoplasm - Active peptic ulcer disease last 60 day upper gastrointestinal bleeding time life - Known allergy drug clopidogrel , ranitidine omeprazole - Refuse participate study ] Methodology : The study double-blind , double-dummy prospective design . Clopidogrel action evaluate platelet function test : VerifyNow , bioimpedance aggregometry Platelet Function Analyzer-100 ( PFA-100 ) . The patient measurement platelet function three moment : start clopidogrel ; 1 week DAPT clopidogrel ( without load dose ) plus ASA ; 1 week randomization ranitidin 150 mg bid omeprazole 20 mg bid .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Age &gt; 18 year old Coronary artery disease , define previous myocardial infarction and/or coronary angioplasty and/or CABG surgery and/or coronariography show obstruction least 50 % one major epicardial vessel Treatment Acetylsalicylic Acid ( ASA ) 100 mg/day Use last 7 day antiplatelet drug beside ASA oral anticoagulant Previous utilization PPI ranitidine last 7 day randomization Any active bleeding Pregnancy woman childbearing age without contraceptive method Hemoglobin &lt; 10 g/dL hematocrit &lt; 30 % , hematocrit &gt; 50 % , platelet &lt; 100.000/mm3 &gt; 500.000/mm3 ; creatinin clearance &lt; 50 ml/minute Percutaneous coronary intervention ( PCI ) last 30 day randomization ( PCI last year drugeluted stent use ) ; CABG surgery last 90 day ; acute coronary syndrome last 60 day Active malignant neoplasm Active peptic ulcer disease last 60 day upper gastrointestinal bleeding time life Known allergy drug clopidogrel , ranitidine omeprazole Refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>omeprazole</keyword>
	<keyword>ranitidin</keyword>
	<keyword>interaction</keyword>
	<keyword>aggregability</keyword>
</DOC>